Asthma Trials May Need More Pediatric Focus After GSK’s Mepolizumab, Breo Ellipta Woes
Executive Summary
Mepolizumab seems headed for approval in severe asthma – but only in adults; adolescent data in pivotal studies were promising, but too limited.
You may also be interested in...
Breo Ellipta Stumbles On Pediatric Asthma Claim, But Advair Helps Break The Fall
FDA approves GlaxoSmithKline’s LABA/inhaled corticosteroid combo for asthma in adults but says more data needed in adolescents. GSK plans to throw additional promotional support behind the existing pediatric asthma claim for Advair, which is expected to face generic competition in the coming years.
FDA’s Pediatric Data-Extrapolation Policies Questioned At Asthma Panel
Should using adult data to label a product for kids be ‘a judgment call?’ Advisory committee asks whether FDA needs more explicit criteria during review of GSK’s Breo Ellipta.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.